Dynacure
  • About
    • Company
    • Management
    • Supervisory Board
  • Disease Area
  • Pipeline
    • DYN 101
    • Clinical Trials
    • Antisense technology
    • Publications
  • Patients And Families
  • Investors
  • News / Events
    • News
    • Events
  • Contact
Select Page

Lynn sends us a message

Near Nijmegen, The Netherlands, you’ll find the brilliant and quite clever Lynn. She is not one to let a diagnosis of CNM hold her back from having fun! She plays wheelchair basketball, has a bunch of favorite TV shows, and loves to read.

Read Lynn's Story

message

understood

ABOUT DYNACURE

Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs.  Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.

DISCOVER MORE
Copyright © 2018 - Dynacure